DISCLOSURE
The authors have no conflicts.
REFERENCES
- "Adverse Drug Events." Health.gov, Office of Disease Prevention and Health Promotion, 16 Apr. 2019, health.gove/hcq/ade.asp.
- Bevil CW. Medication management in an elderly, community-based population: a pilot project. J N Y State Nurses Assoc. Jun 1981;12(2):19-29.
- Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. May 2001;30(3):205-211.
- Look KA, Mott DA. Multiple pharmacy use and types of pharmacies used to obtain prescriptions. J Am Pharm Assoc (2003). Nov-Dec 2013;53(6):601-610.
- Chen CB, Abe R, Pan RY, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res. 2018;2018:6431694.
- Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. Aug 2013;69(2):173 e171-113; quiz 185-176.
- Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens- Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. Oct 2011;128(4):723-728.
- Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA. Jun 4 2014;311(21):2231-2232.
- Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. Jan 1993; 129(1):92-96.
- Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/ toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70:539–48.
AUTHOR CORRESPONDENCE
Helena B. Pasieka MD MS Helena.B.Pasieka@medstar.net